NCT06859346CompletedNot Applicable
A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Study to Assess the Effect of Tisina Complex on Cognitive Health in Individuals With Mild Cognitive Impairment
Vedic Lifesciences Pvt. Ltd.16 sites in 1 country84 target enrollmentStarted: April 1, 2025Last updated:
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
- Enrollment
- 84
- Locations
- 16
- Primary Endpoint
- To asses the effect of Tisina complex on improvement in Cognition status (attention, memory, fluency, language, Visuospatial) as assessed by Addenbrooke's Cognitive Examination III (ACE III) as compared to baseline and placebo.
Study Overview
Brief Summary
The present study is a randomized, placebo-controlled, double-blind, parallel-group clinical study designed to assess the effects of IP in individuals with mild cognitive impairment and Tinnitus as compared to a placebo. Approximately 112 individuals aged between 30 and 75years will be screened. Considering a screen failure of 25%, approximately 84 individuals will be randomized in a ratio of 1:1 to receive either the active or placebo. The study will have at least 64 completed participants i.e. 32 participants in each study arm after accounting for adropout/withdrawal rate of 25% at the end of the study. The intervention and follow up duration for all the study participants will be 90 days.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 30 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Males and females between 30 - 75 years old (both values included).
- •Individuals with mild cognitive impairment as indicated by Addenbrooke's Cognitive Examination (ACE) III score between 61 - 82 (both values included).
- •Individuals with subjective tinnitus with normal hearing or up to moderate sensorineural hearing loss for more than 6 months' duration.
- •Tinnitus maskable with noise of at least 5 decibels assessed by audiometry.
- •Individuals with a THI score between 18 to 56 (both values included).
- •Progressive cognitive complaints like stress, disturbed sleep etc. reported by participant or caregiver.
- •Individuals willing to provide a signed and dated informed consent and authorization to use personal health information in accordance with local and national guidance and regulations.
- •Individuals willing to comply with all procedures as outlined in the informed consent.
Exclusion Criteria
- •Individuals with a medical history of heart disease, respiratory disorders, seizure disorders, metabolic syndrome or other chronic health conditions requiring medication.
- •Clinically diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)
- •Clinically diagnosed with Alzheimer's disease.
- •Individuals with clinically significant psychiatric or neurological states, neurodegenerative disorders such as Parkinson's disease & fronto-temporal dementia, etc, that may account for cognitive impairment.
- •Individuals of objective (pulsatile) tinnitus.
- •Individuals suffering with any congenital anomalies which may lead to any otological problem.
- •Individuals suffering from any infective otological problem.
- •Individuals suffering from any otological problem other than tinnitus and sensorineural hearing.
- •Individuals whose tinnitus resulted from acute acoustic trauma, sudden deafness or traumatic head or neck injury.
- •Individuals taking any ototoxic or potentially tinnitus-inducing medication (e.g., aminoglycosides, chemotherapeutics, loop diuretics, high doses of aspirin or quinine).
- •Individuals with Meniere's disease, otosclerosis and acute or chronic otitis media.
- •Individuals with history and/or presence significant gastrointestinal disease, active malignant diseases, autoimmune diseases, haemorrhagic diathesis, cardiovascular, renal or hepatic disorders, psychiatric disorders, thyroid disease or any other acute or chronic disease.
- •Individuals who are not willing to maintain their medication, diet or physical activity habits during the study.
- •Individuals with uncontrolled Hypertension with systolic blood pressure more than or equal to 140 and/or diastolic blood pressure more than or equal to 90 mm Hg.
- •Individuals with FBG more than or equal to 126 mg/dl.
- •Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) values exceeding 2 times the upper normal limit.
- •Serum creatinine levels exceeding 1.5 times the upper normal limit.
- •Head injury immediately preceding cognitive deterioration.
- •History of uncontrolled migraine headaches, severe sleep disorders.
- •Use of psychotropic drugs or any other drug or supplement such as nootropics that may significantly affect cognitive functioning during the month prior to psychometric testing.
- •Use of any experimental medication or OTC medication or herbal treatment such as hesperidin, diosmin and other flavonoids within 1 month prior to screening.
- •Females taking any oral contraceptives.
- •Current smokers.
- •Consumption of excessive amount of caffeine i.e. ≥ 4 cups daily (> 500 mg per day).
- •History of drug, substance or alcohol addiction or abuse within the past 12 months.
- •Prior participation in a clinical study in the past 90 days before screening.
- •Females who are pregnant/planning to be pregnant or currently lactating.
Arms & Interventions
Arm 1: TisinaTM complex
Active Comparator
Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
Intervention: Arm 1: TisinaTM complex (Dietary Supplement)
Arm 2: Placebo (Microcrystalline Cellulose)
Placebo Comparator
Route of administration: Oral. Dose: 500 mg (2 caplets) at a single time. Regimen: Take 2 caplets, three times a day (total of 6 caplets daily) with meals.
Intervention: Arm 2: Placebo (Microcrystalline Cellulose) (Dietary Supplement)
Outcomes
Primary Outcomes
To asses the effect of Tisina complex on improvement in Cognition status (attention, memory, fluency, language, Visuospatial) as assessed by Addenbrooke's Cognitive Examination III (ACE III) as compared to baseline and placebo.
Time Frame: Day 0, Day 20, Day 45 and Day 90]
On Day 0, participants will receive study instructions. Cognitive status will be assessed on Days 20, 45, and 90 to evaluate symptom improvement and the efficacy of the investigational product (IP) compared to baseline and placebo.
Secondary Outcomes
- To asses the effect of Tisina complex in comparison to baseline and placebo on Loudness, distress, and QOL in Tinnitus as assessed by Tinnitus Visual Analog Scale (TVAS).(Day 0, Day 20, Day 45 and Day 90)
- To asses the effect of Tisina complex in comparison to baseline and placebo on severity of tinnitus for Tinnitus loudness , Tinnitus frequency pitch, and Minimum masking level (MML) by Audiometric tests.(Day 0, Day 20, Day 45 and Day 90)
- To asses the effect of Tisina complex in comparison to baseline and placebo on Change in Subjective discomfort due to Tinnitus as assessed by Tinnitus Handicap inventory (THI).(Day 0, Day 20, Day 45 and Day 90)
- To asses the effect of Tisina complex in comparison to baseline and placebo on stress as assessed by the Perceived Stress Scale (PSS).(Day 0, Day 20, Day 45 and Day 90)
- To asses the effect of Tisina complex in comparison to baseline and placebo on Quality of life as assessed by "Quality of Life in Neurological Disorders" questionnaire for Sleep and cognition function.(Day 0, Day 20, Day 45 and Day 90)
Investigators
Study Sites (16)
Loading locations...
Similar Trials
Completed
Not Applicable
A Study to Assess the Effect of the Bio-K+ Probiotic Capsules (VL-BK-02) in Adults With Functional ConstipationFunctional ConstipationNCT06730594Vedic Lifesciences Pvt. Ltd.168
Completed
Not Applicable
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBSDiarrhea-Predominant Irritable Bowel SyndromeNCT06346847A-Mansia Biotech S.A.384
Not yet recruiting
Not Applicable
A Study to Assess the Effect of Libifem® (VL-GF-01) on Fertility in Women With Diminished Ovarian ReserveNCT06826716Vedic Lifesciences Pvt. Ltd.150
Completed
Not Applicable
A Study to Assess the Gut Health Effects of Heat-killed Post-biotics in Overweight and Obese AdultsGastrointestinal DysfunctionNCT05820737Vedic Lifesciences Pvt. Ltd.155
Completed
Not Applicable
A Study to Assess the Gut Health Effects of Oil Compound on Healthy AdultsGut HealthNCT05837754Vedic Lifesciences Pvt. Ltd.102